Alphabet is funding a new way to reduce heart disease, the leading cause of death in the US

Alphabet's GV and Verily are getting behind an ambitious biotech venture that aims to develop a new treatment for cardiovascular disease.

from Tech https://cnb.cx/2JHDRF6